Lineage Cell Therapeutics, Inc.LCTXNYSE
Loading
SG&A Expenses Over TimeStable
Percentile Rank57
3Y CAGR-6.4%
5Y CAGR+3.5%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
-6.4%/yr
vs -2.3%/yr prior
5Y CAGR
+3.5%/yr
Recent deceleration
Acceleration
-4.1pp
Decelerating
Percentile
P57
Within normal range
vs 5Y Ago
1.2x
Modest growth
Streak
2 yr
Consecutive growthStable
PeriodValueYoY Change
TTM$18.46M+1.6%
2024$18.17M+5.0%
2023$17.30M-23.1%
2022$22.51M+23.6%
2021$18.21M+17.0%
2020$15.57M-35.2%
2019$24.03M-2.8%
2018$24.73M+24.1%
2017$19.92M-29.9%
2016$28.43M-